Literature DB >> 11081635

Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis.

B Motyka1, G Korbutt, M J Pinkoski, J A Heibein, A Caputo, M Hobman, M Barry, I Shostak, T Sawchuk, C F Holmes, J Gauldie, R C Bleackley.   

Abstract

The serine proteinase granzyme B is crucial for the rapid induction of target cell apoptosis by cytotoxic T cells. Granzyme B was recently demonstrated to enter cells in a perforin-independent manner, thus predicting the existence of a cell surface receptor(s). We now present evidence that this receptor is the cation-independent mannose 6-phosphate/insulin-like growth factor receptor (CI-MPR). Inhibition of the granzyme B-CI-MPR interaction prevented granzyme B cell surface binding, uptake, and the induction of apoptosis. Significantly, expression of the CI-MPR was essential for cytotoxic T cell-mediated apoptosis of target cells in vitro and for the rejection of allogeneic cells in vivo. These results suggest a novel target for immunotherapy and a potential mechanism used by tumors for immune evasion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11081635     DOI: 10.1016/s0092-8674(00)00140-9

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  99 in total

1.  Critical role for perforin-, Fas/FasL-, and TNFR1-mediated cytotoxic pathways in down-regulation of antigen-specific T cells during persistent viral infection.

Authors:  Shenghua Zhou; Rong Ou; Lei Huang; Demetrius Moskophidis
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

2.  Expression of small leucine-rich extracellular matrix proteoglycans biglycan and lumican reveals oral lichen planus malignant potential.

Authors:  Božana Lončar-Brzak; Marko Klobučar; Irena Veliki-Dalić; Ivan Sabol; Sandra Kraljević Pavelić; Božo Krušlin; Marinka Mravak-Stipetić
Journal:  Clin Oral Investig       Date:  2017-08-04       Impact factor: 3.573

Review 3.  Granzyme A activates another way to die.

Authors:  Judy Lieberman
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

4.  Evidence for a perforin-mediated mechanism controlling cardiac inflammation in Trypanosoma cruzi infection.

Authors:  Andrea Henriques-Pons; Gabriel M Oliveira; Mauricio M Paiva; Alexandre F S Correa; Marcos M Batista; Rodrigo C Bisaggio; Chau-Ching Liu; Vinicius Cotta-De-Almeida; Claudia M L M Coutinho; Pedro M Persechini; Tania C Araujo-Jorge
Journal:  Int J Exp Pathol       Date:  2002-04       Impact factor: 1.925

5.  Keys to the hidden treasures of the mannose 6-phosphate/insulin-like growth factor 2 receptor.

Authors:  A Bassim Hassan
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

Review 6.  Effector lymphocytes in islet cell autoimmunity.

Authors:  Pere Santamaria
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

7.  Granule-mediated killing by granzyme B and perforin requires a mannose 6-phosphate receptor and is augmented by cell surface heparan sulfate.

Authors:  Kirstin Veugelers; Bruce Motyka; Ing Swie Goping; Irene Shostak; Tracy Sawchuk; R Chris Bleackley
Journal:  Mol Biol Cell       Date:  2005-11-09       Impact factor: 4.138

8.  High-affinity ligand binding by wild-type/mutant heteromeric complexes of the mannose 6-phosphate/insulin-like growth factor II receptor.

Authors:  Michelle A Hartman; Jodi L Kreiling; James C Byrd; Richard G MacDonald
Journal:  FEBS J       Date:  2009-02-19       Impact factor: 5.542

9.  Cationic sites on granzyme B contribute to cytotoxicity by promoting its uptake into target cells.

Authors:  Catherina H Bird; Jiuru Sun; Kheng Ung; Diana Karambalis; James C Whisstock; Joseph A Trapani; Phillip I Bird
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

10.  Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neu.

Authors:  Yu Cao; Khalid A Mohamedali; John W Marks; Lawrence H Cheung; Walter N Hittelman; Michael G Rosenblum
Journal:  Mol Cancer Ther       Date:  2013-03-14       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.